Skip to content

Patient Registry of Blind Subjects With Sleep-related Problems

Development of a Patient Registry of Blind Subjects With Sleep-related Problems

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01195558
Enrollment
10000
Registered
2010-09-06
Start date
2010-04-30
Completion date
2030-04-30
Last updated
2020-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep-wake Disorder in Blind Individuals

Keywords

Non-24, N24HSWD, Blindness, Sleep, Wake, Circadian Rhythm, Nap

Brief summary

Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.

Interventions

OTHERData collection on blindness and sleep problems

Data related to degree of vision impairment and sleep problems is collected through a phone or web survey

Sponsors

Vanda Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Subjects or legal guardians must be at least 18 years of age to participate in the telephone survey. Parents or legal guardians may represent children from 0 through 17 years who meet the following criteria. 2. Subjects must be blind. 3. Subjects must have some self-described problem with sleep or daytime sleepiness.

Design outcomes

Primary

MeasureTime frame
Number of blind participantsongoing

Secondary

MeasureTime frame
Sleep/wake disruptionsongoing

Countries

United States

Contacts

Primary ContactVanda Pharmaceuticals
(202) 734-3400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026